CHIME模拟模型的开发与验证:用于预测中国人群糖尿病前期和2型糖尿病的终身健康结局
研究基于香港临床管理系统97,628名糖尿病前期或2型糖尿病参与者开发了CHIME模拟模型,包含13个风险方程,并在CHARLS队列4,567名参与者及9项已发表试验的80个观察终点中进行外部验证。CHIME在判别力和校准上优于UKPDS-OM2和RECODe,尤其适用于中国及东亚人群。
要点
- CHIME模型包含13个风险方程,可预测死亡、微血管和大血管并发症及糖尿病发生。
- 在CHARLS外部验证中,CHIME判别力C统计量为0.702至0.770(糖尿病参与者)。
- CHIME预测误差(RMSPE)在CMS为3.53%,低于UKPDS-OM2的10.82%和RECODe的11.16%。
核心结论
- CHIME模型是经过验证的新工具,可预测糖尿病进展及其结局,尤其适用于中国和东亚人群。
研究设计与样本
- 基于香港临床管理系统2006至2017年97,628名糖尿病前期或2型糖尿病参与者开发患者级模拟模型。
- 外部验证使用CHARLS队列2011至2018年4,567名参与者,以及9项已发表试验的80个观察终点。
主要发现
- CHIME风险方程内部判别C统计量为0.636至0.813,外部验证(糖尿病参与者)为0.702至0.770。
- CMS校准斜率范围:死亡、心梗、缺血性心脏病、视网膜病变、神经病变、皮肤溃疡、白内障、肾衰竭和心衰为0.680至1.333;外周血管病0.591;脑血管病1.599;截肢2.247。
- CHARLS校准斜率范围为0.709至1.035。
- CHIME在CMS和CHARLS中判别力和校准均优于UKPDS-OM2;在CMS中判别力略优于RECODe且校准更好。
- CHIME预测误差(RMSPE)在CMS为3.53%,在CHARLS为4.49%;亚洲试验RMSPE为0.48%至3.66%,非亚洲试验为0.81%至8.50%。
关键数值与推荐
- CHIME模型包含13个风险方程,采用参数比例风险模型推导。
- 校准斜率在CMS中范围0.591至2.247,在CHARLS中0.709至1.035。
- 与UKPDS-OM2比较:CMS中C统计量0.548至0.772,斜率0.130至3.846;CHARLS中C统计量0.514至0.750,斜率-0.589至11.411。
- 与RECODe比较:CMS中C统计量0.615至0.793,斜率0.138至1.514。
- RMSPE:CHIME在CMS为3.53%,UKPDS-OM2为10.82%,RECODe为11.16%;CHARLS中CHIME为4.49%,UKPDS-OM2为14.80%。
临床怎么用
- 卫生服务规划者和政策制定者可使用CHIME制定人群层面策略,例如设定HbA1c和血脂目标以优化健康结局。
局限性
- CHARLS队列记录的结果数量有限。
- 模拟队列来源于试验参与者,其普遍性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Existing predictive outcomes models for type 2 diabetes developed and validated in historical European populations may not be applicable for East Asian populations due to differences in the epidemiology and complications. Despite the continuum of risk across the spectrum of risk factor values, existing models are typically limited to diabetes alone and ignore the progression from prediabetes to diabetes. The objective of this study is to develop and externally validate a patient-level simulation model for prediabetes and type 2 diabetes in the East Asian population for predicting lifetime health outcomes. METHODS AND FINDINGS: We developed a health outcomes model from a population-based cohort of individuals with prediabetes or type 2 diabetes: Hong Kong Clinical Management System (CMS, 97,628 participants) from 2006 to 2017. The Chinese Hong Kong Integrated Modeling and Evaluation (CHIME) simulation model comprises of 13 risk equations to predict mortality, micro- and macrovascular complications, and development of diabetes. Risk equations were derived using parametric proportional hazard models. External validation of the CHIME model was assessed in the China Health and Retirement Longitudinal Study (CHARLS, 4,567 participants) from 2011 to 2018 for mortality, ischemic heart disease, cerebrovascular disease, renal failure, cataract, and development of diabetes; and against 80 observed endpoints from 9 published trials using 100,000 simulated individuals per trial. The CHIME model was compared to United Kingdom Prospective Diabetes Study Outcomes Model 2 (UKPDS-OM2) and Risk Equations for Complications Of type 2 Diabetes (RECODe) by assessing model discrimination (C-statistics), calibration slope/intercept, root mean square percentage error (RMSPE), and R2. CHIME risk equations had C-statistics for discrimination from 0.636 to 0.813 internally and 0.702 to 0.770 externally for diabetes participants. Calibration slopes between deciles of expected and observed risk in CMS ranged from 0.680 to 1.333 for mortality, myocardial infarction, ischemic heart disease, retinopathy, neuropathy, ulcer of the skin, cataract, renal failure, and heart failure; 0.591 for peripheral vascular disease; 1.599 for cerebrovascular disease; and 2.247 for amputation; and in CHARLS outcomes from 0.709 to 1.035. CHIME had better discrimination and calibration than UKPDS-OM2 in CMS (C-statistics 0.548 to 0.772, slopes 0.130 to 3.846) and CHARLS (C-statistics 0.514 to 0.750, slopes -0.589 to 11.411); and small improvements in discrimination and better calibration than RECODe in CMS (C-statistics 0.615 to 0.793, slopes 0.138 to 1.514). Predictive error was smaller for CHIME in CMS (RSMPE 3.53% versus 10.82% for UKPDS-OM2 and 11.16% for RECODe) and CHARLS (RSMPE 4.49% versus 14.80% for UKPDS-OM2). Calibration performance of CHIME was generally better for trials with Asian participants (RMSPE 0.48% to 3.66%) than for non-Asian trials (RMPSE 0.81% to 8.50%). Main limitations include the limited number of outcomes recorded in the CHARLS cohort, and the generalizability of simulated cohorts derived from trial participants. CONCLUSIONS: Our study shows that the CHIME model is a new validated tool for predicting progression of diabetes and its outcomes, particularly among Chinese and East Asian populations that has been lacking thus far. The CHIME model can be used by health service planners and policy makers to develop population-level strategies, for example, setting HbA1c and lipid targets, to optimize health outcomes.
引用
- Quan J, Ng CS, Kwok HHY, et al. Development and validation of the CHIME simulation model to assess lifetime health outcomes of prediabetes and type 2 diabetes in Chinese populations: A modeling study. PLoS Med. 2021. PMID: 34166382. doi:10.1371/journal.pmed.1003692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。